
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Combination therapy has proven effective in treating vitiligo in a small number of patients, according to research presented at the annual meeting of the American Society of Dermatologic Surgeons, held here last month.






